Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
复制标题
DOI：
--
复制
发表时间：
1990-07
期刊：
影响因子：
11.2
通讯作者：
A. Berchuck;R. Whitaker;G. Olt;J. Soper;D. Clarke‐Pearson;A. Kamel;A. Kamel;R. Bast;B. Kerns;R. Kinney;R. Dodge;P. Marks;S. McKenzie;S. Yin
中科院分区：
文献类型：
--
作者：
A. Berchuck;R. Whitaker;G. Olt;J. Soper;D. Clarke‐Pearson;A. Kamel;A. Kamel;R. Bast;B. Kerns;R. Kinney;R. Dodge;P. Marks;S. McKenzie;S. Yin
先前的研究表明，HER-2/neu癌基因过表达发生在15-40%的乳腺癌中，并且过表达与预后不良有关。在本报告中，我们使用了免疫组织化学技术，涉及与HER-2/neu外部结构域特异性反应的单克隆抗体，研究了HER-2/neu在正常卵巢和晚期上皮性卵巢癌冷冻切片中的表达。正常卵巢上皮HER-2neu染色强度一般为中等或以下（0-2+）。在73例卵巢癌中，50例（68%）的染色与正常卵巢上皮相似（0-2+），23例（32%）染色较重（3+）。23例HER-2/neu高表达患者的生存期（中位，15.7个月）显著低于50例HER-2/neu正常表达患者（中位，32.8个月）。此外，HER-2/neu高表达的肿瘤患者对初始治疗的完全反应（P < 0.05）或术前血清CA 125水平正常时复诊阴性的可能性显着降低（P < 0.05）。这些发现提示HER-2/neu作为上皮性卵巢癌的预后标志物值得进一步评估。
Previous studies have suggested that overexpression of HER-2/neu oncogene occurs in 15-40% of breast cancers and that overexpression is associated with poor prognosis. In the present report, we have used an immunohistochemical technique involving a monoclonal antibody specifically reactive with the external domain of HER-2/neu to study expression of HER-2/neu in frozen sections of normal ovary and advanced epithelial ovarian cancer. The intensity of staining for HER-2neu was always moderate or less (0-2+) in normal ovarian epithelium. Among 73 ovarian cancers, 50 (68%) had staining similar to that for normal ovarian epithelium (0-2+) while 23 (32%) stained heavily (3+). Survival of the 23 patients with high HER-2/neu expression (median, 15.7 months) was significantly worse (P = 0.001) than that of the 50 patients (median, 32.8 months) with normal HER-2/neu expression. In addition, patients whose tumors had high HER-2/neu expression were significantly less likely to have a complete response to primary therapy (P less than 0.05) or have a negative second-look laparotomy when serum CA 125 levels were normal preoperatively (P less than 0.05). These findings suggest that HER-2/neu deserves further evaluation as a prognostic marker in epithelial ovarian cancer.